Athanassios Argiris reports on key results from ESMO Congress 2021 on LBA36 - CheckMate 651, a phase III trial of nivolumab/ipilimumab versus EXTREME regimen in first-line treatment of recurrent or metastatic SCCHN
20 Sep 2021 Proffered Paper session - Head and neck cancer, excl. thyroid